Physician profile
John J Ziebert
NPI 1205811296
$14,130.53
in general payments reported to CMS, 2019-2025
39 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,237 · 2020: $1,943 · 2021: $2,654 · 2022: $2,501 · 2023: $1,748 · 2024: $1,591 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,663 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,663.15 |
| Education | $132.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,436.35 | 2019-2025 | Rinvoq, Mavyret, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,393.78 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,095.02 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $978.67 | 2019-2025 | |
| Pfizer INC. | $914.49 | 2019-2025 | |
| Celgene Corporation | $590.27 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $574.00 | 2020-2023 | Injectafer |
| Janssen Biotech, INC. | $391.34 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $377.74 | 2022-2024 | Stelara, Remicade, Tremfya |
| Allergan, INC. | $347.90 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $202.09 | 2020-2023 | |
| Romark Laboratories, Lc | $182.90 | 2019-2020 | |
| Genzyme Corporation | $173.16 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $151.11 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $146.63 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $115.64 | 2020-2023 | Sutab |
| Qol Medical, LLC | $101.31 | 2019-2025 | Sucraid |
| Lilly USA, LLC | $100.65 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $89.28 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $85.63 | 2019-2022 | |
| Celltrion USA INC. | $83.97 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Sandoz INC. | $81.23 | 2023-2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $80.88 | 2023-2024 | Dupixent |
| Ucb, INC. | $71.06 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $58.67 | 2019-2023 | Ocaliva |
| Redhill Biopharma INC. | $45.76 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Astrazeneca Pharmaceuticals LP | $36.65 | 2019 | |
| Vivus LLC | $35.85 | 2022-2025 | Pancreaze |
| Shire North American Group INC | $32.21 | 2019 | |
| Aimmune Therapeutics, INC. | $30.75 | 2024-2025 | Zenpep |
| Dova Pharmaceuticals | $20.33 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.68 | 2023 | Rebyota |
| Ethicon US, LLC | $17.77 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.54 | 2024 | Iqirvo |
| Merck Sharp & Dohme LLC | $15.90 | 2019 | |
| Orphalan INC | $14.32 | 2025 | Cuvrior |
| Organon LLC | $11.57 | 2022 | |
| Saluda Medical Americas, INC. | $8.43 | 2024 | Evoke |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ziebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.